Anti-histamines and Methacholine Challenges.
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Registration Number
- NCT01985789
- Lead Sponsor
- Don Cockcroft
- Brief Summary
The asthmatic airway is identified and studied using inhaled agents such as histamine and methacholine. The use of antihistamines prior to the test will inhibit the test result if histamine is used to cause airway constriction. If using methacholine, this may also be true depending on whether old (e.g. benadryl) or new (e.g. desloratadine) antihistamines are used. This study will look at the effect of old and new antihistamines on inhaled methacholine challenge response in individuals with mild asthma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
- Baseline forced expiratory volume in 1s (FEV1) of 70% or more of predicted
- Methacholine provocative concentration causing a 20% fall in FEV1 16mg/ml or less
- No respiratory infection or change in allergen exposure for 4 weeks prior to screening and throughout the study
- No significant medical co-morbidities
- allergy
Exclusion Criteria
- pregnant or breastfeeding females
- unable to withhold antihistamines, anticholinergics, long acting bronchodilators and combination therapies
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description placebo placebo given as 2 placebo capsules diphenhydramine Diphenhydramine 50mg dose given as two 25mg capsules cetirizine cetirizine 10mg dose given as 1 10mg capsule and 1 placebo capsule desloratadine desloratadine 5mg dose given as 1 5mg capsule and 1 placebo capsule
- Primary Outcome Measures
Name Time Method change in methacholine pc20 change from baseline (pre dose) at 2 hours (post dose)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Saskatchewan
🇨🇦Saskatoon, Saskatchewan, Canada